These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 29848573)

  • 1. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
    Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
    Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
    Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
    Radvanyi LG; Bernatchez C; Zhang M; Fox PS; Miller P; Chacon J; Wu R; Lizee G; Mahoney S; Alvarado G; Glass M; Johnson VE; McMannis JD; Shpall E; Prieto V; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Patel S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Davies MA; Mansaray R; Fulbright OJ; Toth C; Ramachandran R; Wardell S; Gonzalez A; Hwu P
    Clin Cancer Res; 2012 Dec; 18(24):6758-70. PubMed ID: 23032743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.
    Zippel D; Friedman-Eldar O; Rayman S; Hazzan D; Nissan A; Schtrechman G; Markel G; Schachter J; Itzhaki O; Besser MJ
    Anticancer Res; 2019 Sep; 39(9):4995-5001. PubMed ID: 31519606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
    Dudley ME; Gross CA; Langhan MM; Garcia MR; Sherry RM; Yang JC; Phan GQ; Kammula US; Hughes MS; Citrin DE; Restifo NP; Wunderlich JR; Prieto PA; Hong JJ; Langan RC; Zlott DA; Morton KE; White DE; Laurencot CM; Rosenberg SA
    Clin Cancer Res; 2010 Dec; 16(24):6122-31. PubMed ID: 20668005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
    Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
    Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.
    Fortman D; Karunamurthy A; Hartman D; Wang H; Seigh L; Abukhiran I; Najjar YG; Pantanowitz L; Zarour HM; Kirkwood JM; Davar D
    Oncologist; 2024 Jul; 29(7):619-628. PubMed ID: 38655867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
    Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
    Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.
    Martín-Lluesma S; Svane IM; Dafni U; Vervita K; Karlis D; Dimopoulou G; Tsourti Z; Rohaan MW; Haanen JBAG; Coukos G
    Ann Oncol; 2024 Oct; 35(10):860-872. PubMed ID: 39053767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
    Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
    World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma.
    Zhou X; Wu J; Duan C; Liu Y
    J Immunol Res; 2020; 2020():7890985. PubMed ID: 33062726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
    Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
    Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
    Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
    Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
    Seitter SJ; Sherry RM; Yang JC; Robbins PF; Shindorf ML; Copeland AR; McGowan CT; Epstein M; Shelton TE; Langhan MM; Franco Z; Danforth DN; White DE; Rosenberg SA; Goff SL
    Clin Cancer Res; 2021 Oct; 27(19):5289-5298. PubMed ID: 34413159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.